Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al.

J Infect Dis. 1995 Mar;171(3):537-45.

PMID:
7533197
2.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.

PMID:
7530585
3.

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

de Jong MD, Vella S, Carr A, Boucher CA, Imrie A, French M, Hoy J, Sorice S, Pauluzzi S, Chiodo F, Weverling GJ, van der Ende ME, Frissen PJ, Weigel HM, Kauffmann RH, Lange JM, Yoon R, Moroni M, Hoenderdos E, Leitz G, Cooper DA, Hall D, Reiss P.

J Infect Dis. 1997 Apr;175(4):966-70.

4.

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, et al.

J Virol. 1994 Mar;68(3):1660-6.

5.

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.

Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL.

J Infect Dis. 1996 Oct;174(4):713-21.

6.

Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.

Kappes JC, Saag MS, Shaw GM, Hahn BH, Chopra P, Chen S, Emini EA, McFarland R, Yang LC, Piatak M Jr, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):139-49.

PMID:
7552477
7.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
8.
9.

Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.

Reedijk M, Boucher CA, van Bommel T, Ho DD, Tzeng TB, Sereni D, Veyssier P, Jurriaans S, Granneman R, Hsu A, et al.

Antimicrob Agents Chemother. 1995 Jul;39(7):1559-64.

10.
11.

Nevirapine: new drug, new class, new questions.

Mascolini M.

J Int Assoc Physicians AIDS Care. 1996 Jul;2(7):8-13.

PMID:
11363750
12.

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R, et al.

J Infect Dis. 1994 Jun;169(6):1346-50.

PMID:
8195615
14.

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.

Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ.

Antimicrob Agents Chemother. 1993 Feb;37(2):178-82.

15.

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E.

J Infect Dis. 2002 Mar 1;185(5):599-607. Epub 2002 Feb 14.

16.

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, et al.

J Infect Dis. 1995 Jun;171(6):1411-9.

PMID:
7539472
17.

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

Balzarini J, Karlsson A, Pérez-Pérez MJ, Camarasa MJ, De Clercq E.

Virology. 1993 Oct;196(2):576-85.

PMID:
7690501
18.
19.

Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.

Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Datema R, Charpiot B, Seifert J, Kaneshima H, McCune JM.

Antimicrob Agents Chemother. 1996 Mar;40(3):755-62.

20.

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A.

J Infect Dis. 1999 May;179(5):1116-23.

Items per page

Supplemental Content

Write to the Help Desk